Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11766142 | 0.83 | GABRA1 (0.42) | TAAR1GABRA1GABRG2GABRB3TSHR | |
| SCHEMBL110369 | 0.83 | AKR1B1 (0.52) | AKR1B1SMN1; SMN2TAAR1GAAKMT2A | |
| SCHEMBL21768187 | 0.79 | TAAR1 (0.43) | AKR1B1SMN1; SMN2TAAR1GAAKMT2A | |
| SCHEMBL30831843 | 0.79 | TAAR1 (0.43) | AKR1B1SMN1; SMN2TAAR1GAAKMT2A | |
| SCHEMBL31454412 | 0.77 | TAAR1 (0.41) | AKR1B1SMN1; SMN2TAAR1GAALMNA | |
| SCHEMBL14370502 | 0.77 | TAAR1 (0.41) | AKR1B1SMN1; SMN2TAAR1GAAKMT2A | |
| SCHEMBL1627393 | 0.77 | TAAR1 (0.41) | AKR1B1SMN1; SMN2TAAR1GAALMNA | |
| SCHEMBL1626950 | 0.75 | AKR1B1 (0.74) | AKR1B1SMN1; SMN2GAAKMT2AADRA2A | |
| SCHEMBL692568 | 0.74 | TSHR (0.52) | AKR1B1SMN1; SMN2TAAR1GAAKMT2A | |
| SCHEMBL2660504 | 0.74 | AKR1B1 (0.45) | AKR1B1SMN1; SMN2TAAR1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3368539-B1 | SUBSTITUTED INDAZOLE COMPOUNDS AS ROR GAMMA T INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3368516-B1 | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2020-07-15 | — | — | EP | disclosed |
| EP-3368516-B1 | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2020-07-15 | — | — | EP | disclosed |
| US-10689369-B2 | Substituted indazole compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10689369-B2 | Substituted indazole compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190276438-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2019-09-12 | — | — | US | disclosed |
| US-20190276438-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2019-09-12 | — | — | US | disclosed |
| US-10344000-B2 | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10344000-B2 | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10287272-B2 | Substituted indazole compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2019-05-14 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| CN-101374516-A | Use of substituted 2-imidazole of imidazoline derivatives | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | CN | disclosed |
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276438-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | RORB, RORC, RORA | AKR1B1 1534/4885SMN1; SMN2 3980/4885TAAR1 2615/4885 |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | AKR1B1 480/4885SMN1; SMN2 1545/4885TAAR1 117/4885 |
| US-10287272-B2 | Substituted indazole compounds as RORgammaT inhibitors and uses thereof | RORB, RORC, RORA | AKR1B1 1484/4885SMN1; SMN2 3966/4885TAAR1 2526/4885 |
| US-10689369-B2 | Substituted indazole compounds as RORgammaT inhibitors and uses thereof | RORB, RORC, RORA | AKR1B1 1534/4885SMN1; SMN2 3980/4885TAAR1 2615/4885 |
| US-10344000-B2 | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof | RORB, RORC, RORA | AKR1B1 1077/4885SMN1; SMN2 4284/4885TAAR1 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.